Acute Treatment of Breakthrough Migraine Study

Breakthrough Migraine Trials in Columbus

Aventiv Research is currently participating in an acute treatment of breakthrough migraine study at our Columbus, Ohio location. A proportion of individuals receiving preventive monotherapy for migraine may continue to experience migraine attacks and migraine-related disability. Atogepant has demonstrated effectiveness in significantly reducing the number of migraine and headache days in patients with episodic migraine. Ubrogepant has been approved by the FDA for the acute treatment of migraine with or without aura in adults.

Enroll Now

Acute Treatment of Breakthrough Migraine Clinical Trial

This open-label study is being conducted to evaluate the safety, tolerability, and effectiveness of the concomitant use of ubrogepant for the acute treatment of breakthrough migraine headache in subjects taking atogepant once daily for the preventive treatment of episodic migraine. You maybe be eligible to participate in this study if you:

• Are 18 to 30 years of age
• Have experienced migraines for 1 year or more, starting before age 50
• Have had migraines 4-14 days per month in each of the last 3 months